Generate Biomedicines (GENB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.68B and a free-cash-flow yield of -13.6%. Over the most recent reported fiscal year, revenue grew 55.9%. Nama's AI scorecard rates it Sell, 2.1 out of 10.
AI scorecard
Sell · 2.1/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-42.4%
How far the last close sits under the highest price of the past five years.
Market cap
$1.68B
Trailing P/E
—
Price / book
3.7
Price / sales
62.2
FCF yield
-13.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
-1134.2%
Net margin
0.0%
Revenue growth (YoY)
+55.9%
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
GENB earnings
Next report: Nov 10, 2026 (Q3 2026, EPS estimate -$0.55).
Beat the EPS estimate in 0 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.52
-$0.49
-6.1%
$6.31M
Q1 2026
May 7, 2026
-$1.07
-$0.51
-109.8%
$7.22M
GENB analyst price target
Median target $27.00 from 5 analysts, ranging $22.00 – $30.00.
Nama's AI scorecard currently rates Generate Biomedicines Sell (2.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GENB report earnings?
Generate Biomedicines's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.55.
What is the GENB price target?
The median analyst price target from 5 analysts is $27.00, with a range of $22.00 – $30.00.
Is GENB Shariah compliant?
Nama's AAOIFI-style screen reads Generate Biomedicines as Not Shariah Compliant. At least one of the three ratios or the industry test failed.